Frank\u00adfurt a. M. \u2014 The Neur\u00adax\u00adph\u00adarm Group has acqui\u00adred two product port\u00adfo\u00adlios from Sanofi, which are marke\u00adted globally in over 50 count\u00adries. With the pending acqui\u00adsi\u00adtion, Neur\u00adax\u00adph\u00adarm aims to streng\u00adthen its posi\u00adtion as a leading Euro\u00adpean specialty phar\u00admaceu\u00adti\u00adcal company focu\u00adsed on central nervous system disor\u00adders and expand its global foot\u00adprint. The acqui\u00adsi\u00adtion of the port\u00adfo\u00adlios will increase Neur\u00adax\u00adphar\u00adm\u2019s annual gross sales to appro\u00adxi\u00adm\u00adately \u20ac0.6 billion. \u2014 Inter\u00adna\u00adtio\u00adnal law firm Clif\u00adford Chance advi\u00adsed Neur\u00adax\u00adph\u00adarm Group on the acqui\u00adsi\u00adtion of the two product port\u00adfo\u00adlios from Sanofi.<\/p>\n
The initial port\u00adfo\u00adlio includes a range of products targe\u00adting central nervous system disor\u00adders, cove\u00adring the areas of psych\u00adia\u00adtry and neuro\u00adlogy \u2014 inclu\u00adding the drugs Nozinan, Tran\u00adxene, Tiapri\u00addal, Dogma\u00adtil and Largac\u00adtil. The second port\u00adfo\u00adlio includes Topal\u00adgic and Tren\u00adtal, two products for the treat\u00adment of pain and vascu\u00adlar dise\u00ada\u00adses. The drugs are used in a variety of pati\u00adents with diffe\u00adrent condi\u00adti\u00adons, inclu\u00adding depres\u00adsion, anxiety, psycho\u00adsis, alco\u00adhol depen\u00addence, myasthe\u00adnia gravis and Parkin\u00adson\u2019s dise\u00adase. Both product port\u00adfo\u00adlios comprise 17 mole\u00adcu\u00adles marke\u00adted under 38 brands.<\/p>\n
About Neur\u00adax\u00adph\u00adarm<\/strong><\/p>\n Neur\u00adax\u00adph\u00adarm is a port\u00adfo\u00adlio group of the private equity fund Perm\u00adira. Clif\u00adford Chance had alre\u00adady advi\u00adsed global private equity firm Perm\u00adira on the acqui\u00adsi\u00adtion of Neur\u00adax\u00adph\u00adarm Group in 2020.<\/p>\n Advi\u00adsor Neur\u00adax\u00adph\u00adarm Group: Clif\u00adford Chance About Clif\u00adford Chance<\/strong><\/p>\n Clif\u00adford Chance, one of the worl\u00add\u2019s leading law firms, is present for its clients with around 3,400 legal advi\u00adsors in all major busi\u00adness centers around the world. Frank\u00adfurt a. M. \u2014 The Neur\u00adax\u00adph\u00adarm Group has acqui\u00adred two product port\u00adfo\u00adlios from Sanofi, which are marke\u00adted globally in over 50 count\u00adries. With the pending acqui\u00adsi\u00adtion, Neur\u00adax\u00adph\u00adarm aims to streng\u00adthen its posi\u00adtion as a leading Euro\u00adpean specialty phar\u00admaceu\u00adti\u00adcal company focu\u00adsed on central nervous system disor\u00adders and expand its global foot\u00adprint. The acqui\u00adsi\u00adtion of the portfolios [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":45564,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1368,1369],"tags":[],"class_list":["post-45554","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors"],"yoast_head":"\n
\nLed by part\u00adner Dr. J\u00f6rg Rhiel (Corporate\/Private Equity, Frankfurt).<\/p>\n
\nIn Germany, Clif\u00adford Chance is repre\u00adsen\u00adted by around 300 lawy\u00aders, audi\u00adtors, tax advi\u00adsors and soli\u00adci\u00adtors in D\u00fcssel\u00addorf, Frank\u00adfurt am Main and Munich.<\/p>\n","protected":false},"excerpt":{"rendered":"